Targeting metabolic weaknesses in advanced prostate cancer treatment.
Official title: Targeting Metabolic Vulnerabilities with Synergistic Therapeutic Agents for Treatment of Metastatic Castration-Resistant Prostate Cancer.
Funded at University of Texas at Austin · NIH-10929951 · Data updated 2026-11-12
This study is looking at new ways to treat advanced prostate cancer that doesn't respond to usual treatments by targeting how cancer cells use certain nutrients to survive, and it may involve patients trying out these new treatment combinations.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas at Austin NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project start | August 21, 2023 |
| Project end | August 20, 2026 |
| Funding year | 2024 |
| Award (this year) | $39,539 |
| NIH project number | 5F31CA275318-02 |
| Project ID | NIH-10929951 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer who have not responded to standard therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not progressed to the metastatic stage may not benefit from this research.
What this research studies
This research focuses on developing new therapeutic strategies for metastatic castration-resistant prostate cancer (mCRPC), a stage of prostate cancer that is particularly difficult to treat. The approach involves targeting specific metabolic pathways that cancer cells exploit to survive and resist standard treatments. By inhibiting key enzymes involved in glutamine metabolism, the research aims to enhance the effectiveness of existing therapies and potentially overcome drug resistance. Patients may be involved in trials assessing these new treatment combinations.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced prostate cancer, potentially improving survival rates.
How similar studies have gone: Previous research has shown promise in targeting metabolic pathways in cancer treatment, indicating potential for success with this novel approach.
Where this research is happening
-
University of Texas at Austin
Austin, United States Active
Researchers
- Principal investigator: Hackman, Gabrelle Lavender — University of Texas at Austin
- Study coordinator: Hackman, Gabrelle Lavender
Related research
Other NIH-funded projects on the same topics.
-
Understanding how aggressive cell states emerge in castration-resistant prostate cancer
A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.
-
Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer
Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.
-
Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer
Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.
-
Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy
This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Therapeutic Targeting of Lineage Plasticity in Advanced Prostate Cancer
A cancer research effort aimed at understanding and tackling how aggressive prostate cancers become resistant to standard AR-targeted therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.